James A. Wells

James A. Wells

Auto-generated profile, based on publicly available information

James A. Wells

University of California, San Francisco

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2007 in Nature
Verified
Journal Article
Closed access
PDF file
JWJames A. Wells
James A. Wells
CMChristopher L. McClendon
Christopher L. McClendon

12 May 2017 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
OJOlivier Julien
Olivier Julien
JWJames A Wells
James A Wells
Protease biology is intimately linked to the functional consequences of substrate cleavage events. Human caspases are a family of 12 fate-determining cysteine proteases that are best known for driving cell death, either apoptosis or pyroptosis. More recently, caspases have been shown to be involved in other cellular remodeling events as well including stem cell fate determination, spermatogenesis, and erythroid differentiation. Recent global proteomics methods enable characterization of the substrates that caspases cleave in live cells and cell extracts. The number of substrate targets identified for individual caspases can vary widely ranging from only a (few) dozen targets for caspases-4, -5, -9, and -14 to hundreds of targets for caspases-1, -2, -3, -6, -7, and -8. Proteomic studies characterizing the rates of target cleavage show that each caspase has a preferred substrate cohort that sometimes overlaps between caspases, but whose rates of cleavage vary over 500-fold within each group. Determining the functional consequences of discrete proteolytic events within the global substrate pool is a major challenge for the field. From the handful of individual targets that have been studied in detail, there are only a few so far that whose single cleavage event is capable of sparking apoptosis alone, such as cleavage of caspase-3/-7 and BIMEL, or for pyroptosis, gasdermin D. For the most part, it appears that cleavage events function cooperatively in the cell death process to generate a proteolytic synthetic lethal outcome. In contrast to apoptosis, far less is known about caspase biology in non-apoptotic cellular processes, such as cellular remodeling, including which caspases are activated, the mechanisms of their activation and deactivation, and the key substrate targets. Here we survey the progress made in global identification of caspase substrates using proteomics and the exciting new avenues these studies have opened for understanding the molecular logic of substrate cleavage in apoptotic and non-apoptotic processes.

4 January 2021 in Journal of the American Chemical Society
Verified
Journal Article
Open access
ACAdam D. Cotton
Adam D. Cotton
DNDuy P. Nguyen
Duy P. Nguyen
JGJosef A. Gramespacher
Josef A. Gramespacher
ISIan B. Seiple
Ian B. Seiple
JWJames A. Wells
James A. Wells
Targeted protein degradation has emerged as a new paradigm to manipulate cellular proteostasis. Proteolysis-targeting chimeras (PROTACs) are bifunctional small molecules that recruit an E3 ligase to a target protein of interest, promoting its ubiquitination and subsequent degradation. Here, we report the development of antibody-based PROTACs (AbTACs), fully recombinant bispecific antibodies that recruit membrane-bound E3 ligases for the degradation of cell-surface proteins. We show that an AbTAC can induce the lysosomal degradation of programmed death-ligand 1 by recruitment of the membrane-bound E3 ligase RNF43. AbTACs represent a new archetype within the PROTAC field to target cell-surface proteins with fully recombinant biological molecules.

10 February 2017 in Science
Verified
Journal Article
Closed access
SLShixian Lin
Shixian Lin
XYXiaoyu Yang
Xiaoyu Yang
SJShang Jia
Shang Jia
AWAmy M. Weeks
Amy M. Weeks
MHMichael Hornsby
Michael Hornsby
CCChristopher J. Chang
Christopher J. Chang
Targeting proteins at the other sulfur: As the only amino acid with a thiol (SH) group, cysteine is easily targeted for site-selective protein modifications. Hydrophobic methionine also has sulfur in its side chain, but its capping methyl group has hindered analogous targeting efforts. Lin et al. introduce a complementary protocol to tether new substituents exclusively to methionine, even in the presence of cysteine. They used an oxaziridine group as an oxidant to form sulfimide (S=N) linkages. The approach allowed antibody-drug conjugation and chemoproteomic screening for reactive methionine surface residues. Science , this issue p. 597

1 September 2008 in Cell
Verified
Journal Article
Closed access
SMSami Mahrus
Sami Mahrus
JTJonathan C. Trinidad
Jonathan C. Trinidad
DBDavid T. Barkan
David T. Barkan
ASAndrej Sali
Andrej Sali
ABAlma L. Burlingame
Alma L. Burlingame
JWJames A. Wells
James A. Wells

22 September 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
KPKatarina Pance
Katarina Pance
JGJosef A. Gramespacher
Josef A. Gramespacher
JBJames R. Byrnes
James R. Byrnes
FSFernando Salangsang
Fernando Salangsang
Juan Antonio Camara SerranoJuan Antonio Camara Serrano
Juan Antonio Camara Serrano
JWJames A. Wells
James A. Wells
Targeted degradation of cell surface and extracellular proteins via lysosomal delivery is an important means to modulate extracellular biology. However, these approaches have limitations due to lack of modularity, ease of development, restricted tissue targeting and applicability to both cell surface and extracellular proteins. We describe a lysosomal degradation strategy, termed cytokine receptor-targeting chimeras (KineTACs), that addresses these limitations. KineTACs are fully genetically encoded bispecific antibodies consisting of a cytokine arm, which binds its cognate cytokine receptor, and a target-binding arm for the protein of interest. We show that KineTACs containing the cytokine CXCL12 can use the decoy recycling receptor, CXCR7, to target a variety of target proteins to the lysosome for degradation. Additional KineTACs were designed to harness other CXCR7-targeting cytokines, CXCL11 and vMIPII, and the interleukin-2 (IL-2) receptor-targeting cytokine IL-2. Thus, KineTACs represent a general, modular, selective and simple genetically encoded strategy for inducing lysosomal delivery of extracellular and cell surface targets with broad or tissue-specific distribution.